Synthesis: Patient-reported outcomes in TNBC trials

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Why PROs matter

Standard trial efficacy endpoints (PFS, OS, pCR, EFS) measure outcomes that are clinically meaningful but don't directly capture patient experience. A treatment that improves PFS by 3 months while producing severe persistent toxicity may not be net-beneficial from the patient perspective. A treatment with equivalent efficacy but lower toxicity may be substantially preferred even without efficacy advantage. PROs aim to capture these dimensions directly.

In TNBC specifically, PRO data inform several decisions:

• Comparing toxicity profiles of competing first-line metastatic regimens (chemotherapy + IO vs PARP inhibitor in BRCA+, for example)
• Assessing trade-offs between intensive adjuvant therapy and quality of life in residual-disease patients
• Identifying tolerability issues that may drive treatment discontinuation
• Capturing patient-meaningful improvements that clinical observation misses

Principal PRO instruments

EORTC QLQ-C30

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a 30-item instrument measuring multiple domains: physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, global health status, and symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep, appetite, constipation, diarrhea, financial difficulties). It is the most widely used cancer-general PRO instrument internationally and is included in most TNBC trials^[1]A.

EORTC QLQ-BR23 / BR45

Breast cancer-specific module supplementing QLQ-C30. The original 23-item BR23 covers body image, sexual functioning, future perspective, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss. The newer BR45 expands the original module with additional items reflecting modern treatment experiences (immune-related adverse events, ADC-specific toxicities).

FACT-B

The Functional Assessment of Cancer Therapy — Breast (FACT-B) is a US-developed alternative to EORTC QLQ-C30 + BR23, measuring physical, social/family, emotional, and functional well-being plus breast cancer-specific concerns. Widely used in North American trials.

PRO-CTCAE

The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a US National Cancer Institute instrument that translates CTCAE adverse-event terminology into patient-reported language. PRO-CTCAE captures symptomatic adverse events directly from patients, complementing clinician-reported CTCAE grading. Implementation in TNBC trials is increasing.

EQ-5D

A generic health-status instrument used for health-economic evaluation. The EQ-5D-5L produces utility scores used in cost-effectiveness analyses. Required for many regulatory and health-technology-assessment submissions.

Measurement methodology

PRO collection in TNBC trials typically includes:

• Baseline measurement before treatment initiation
• On-treatment measurements at pre-specified intervals (often every 3 weeks during chemotherapy, monthly during maintenance, every 3 months during long-term follow-up)
• End-of-treatment measurement
• Long-term survivorship measurements in adjuvant trials
• Mode: paper, web-based ePRO, or mobile app collection
• Completion rates: usually 80–90% at early timepoints; declining over long-term follow-up

SISAQOL — standardization initiative

The Setting International Standards in Analyzing patient-reported Outcomes and Quality of life endpoints in cancer clinical trials (SISAQOL) initiative published recommendations on analyzing and reporting PRO data in cancer trials^[2]B. Recommendations cover:

• Pre-specification of PRO research questions and primary PRO endpoints
• Statistical analysis methods (mixed-effects models, time-to-deterioration analyses, etc.)
• Handling missing data (multiple imputation, sensitivity analyses)
• Reporting standards (CONSORT-PRO extension)
• Interpretation thresholds (minimal clinically important differences)

Implementation of SISAQOL standards in TNBC trials is increasing but uneven across sponsors and regions.

Regulatory uses of PRO data

FDA and EMA have varying receptiveness to PRO data in regulatory decision-making:

• FDA has approved labeling claims based on PRO data for some oncology indications, particularly when the PRO endpoint is pre-specified, validated, and shows treatment effect with adequate statistical power. The FDA Project Patient Voice initiative is increasing prominence of PRO data in regulatory reviews.
• EMA traditionally has weighted PRO data more heavily than FDA in benefit-risk assessment, particularly for treatments with marginal efficacy advantages but distinctive toxicity profiles.
• Health-technology assessment bodies (NICE in UK, IQWiG in Germany, CADTH in Canada) typically require PRO and quality-adjusted survival data for reimbursement decisions.

The implementation gap

Despite widespread PRO data collection, the impact on clinical decisions and labeling has been modest. Reasons:

• Statistical complexity. Multiple PRO domains tested across multiple timepoints produces multiplicity-correction challenges. Trials rarely pre-specify primary PRO endpoints with adequate statistical power.
• Missing data. Patients who progress or discontinue treatment often stop completing PROs, producing missing-not-at-random data that's difficult to analyze.
• Magnitude of differences. PRO differences between arms in TNBC trials are often statistically significant but clinically small; whether they justify treatment decisions is debated.
• Communication with clinicians. PRO data formats are not always intuitive for clinicians; integration into clinical decision-making requires interpretation expertise.

TNBC-specific PRO findings

Selected TNBC trials have produced informative PRO data:

• OlympiAD and EMBRACA — PARP inhibitor monotherapy produced superior patient-reported outcomes vs single-agent chemotherapy, supporting the claim that PARP inhibitors are not only efficacious but also better tolerated than the comparator chemotherapy choices.
• KEYNOTE-522 — PRO data showed manageable symptom burden during the intensive neoadjuvant + adjuvant regimen, with most domains returning to baseline after treatment completion.
• IMpassion130 — PRO data showed no substantial QoL difference between atezolizumab + nab-paclitaxel and placebo + nab-paclitaxel arms, suggesting the additional drug didn't compromise tolerability despite immune-related AEs.
• ASCENT — sacituzumab govitecan produced symptom-burden patterns reflecting the drug's known GI and hematologic toxicities, but global QoL was maintained.

Real-world PRO collection and electronic monitoring

Electronic PRO (ePRO) collection during routine clinical care is being implemented at multiple academic centers. The PRO-driven symptom monitoring intervention (Basch 2017) demonstrated that ePRO-driven symptom reporting and triggered clinician outreach improved survival and quality of life in metastatic-cancer patients^[3]A. The mechanism is presumed to involve earlier detection and management of symptoms before they become serious.

Implementation of ePRO monitoring in TNBC clinical care is increasing; whether the survival benefits demonstrated in mixed-cancer cohorts replicate in TNBC-specific populations is being studied.

Evidence table

Open questions and active investigation

• Primary-endpoint use of PROs. Whether trials should formally power PRO endpoints as primary or co-primary endpoints (rather than secondary or exploratory) is a methodological and regulatory question. Some trials are taking this approach; results inform feasibility.
• ePRO triage in TNBC routine practice. Whether ePRO-triggered symptom monitoring during TNBC treatment improves outcomes specifically in TNBC (vs the mixed-cancer Basch evidence) is being tested in dedicated trials.
• Survivorship PROs and long-term effects. Long-term PRO collection in TNBC survivors is sparse; understanding the late effects of intensive KEYNOTE-522-era treatment on quality of life requires sustained measurement (see long-term toxicities synthesis when available).
• Differential effects by patient subgroup. Whether PRO outcomes differ by age, racial/ethnic group, socioeconomic status, or geographic region within TNBC trials is being analyzed. Evidence of differential effects could inform tailored intervention strategies.
• Integration with clinician-reported outcomes. Combining PRO and clinician-reported data into composite assessments may produce more informative endpoints than either alone.
• Patient-reported decision aids. PRO data from prior trials can inform decision-aid tools that help patients understand the expected experience of each treatment option. Adoption is limited but growing.

For the broader clinical trial methodology context, see the endpoint design synthesis, the adaptive platform trials synthesis, and the biomarker-stratified design synthesis.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi:10.1093/jnci/85.5.365. ↩
2. Coens C, Pe M, Dueck AC, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol. 2020;21(2):e83–e96. doi:10.1016/S1470-2045(19)30790-9. ↩
3. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017;318(2):197–198. doi:10.1001/jama.2017.7156. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.